NasdaqGS:CPIX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care and gastroenterology in the United States and internationally. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has Cumberland Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CPIX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CPIX's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

3.1%

CPIX

2.9%

US Pharmaceuticals

0.7%

US Market


1 Year Return

-41.9%

CPIX

7.0%

US Pharmaceuticals

22.2%

US Market

Return vs Industry: CPIX underperformed the US Pharmaceuticals industry which returned 7.4% over the past year.

Return vs Market: CPIX underperformed the US Market which returned 22.7% over the past year.


Shareholder returns

CPIXIndustryMarket
7 Day3.1%2.9%0.7%
30 Day2.2%7.3%11.8%
90 Day-6.3%2.1%8.6%
1 Year-41.9%-41.9%9.7%7.0%25.0%22.2%
3 Year-58.5%-58.5%28.6%19.1%49.4%39.5%
5 Year-46.0%-46.0%41.4%25.1%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is Cumberland Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cumberland Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CPIX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CPIX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CPIX is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CPIX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CPIX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CPIX is good value based on its PB Ratio (0.9x) compared to the US Pharmaceuticals industry average (3.6x).


Next Steps

Future Growth

How is Cumberland Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-31.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CPIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CPIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CPIX's revenue is expected to decline over the next 3 years (-10.6% per year).

High Growth Revenue: CPIX's revenue is forecast to decline over the next 3 years (-10.6% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CPIX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cumberland Pharmaceuticals performed over the past 5 years?

-27.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CPIX is currently unprofitable.

Growing Profit Margin: CPIX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CPIX is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.

Accelerating Growth: Unable to compare CPIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CPIX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: CPIX has a negative Return on Equity (-5.31%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cumberland Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CPIX's short term assets ($48.9M) exceed its short term liabilities ($23.9M).

Long Term Liabilities: CPIX's short term assets ($48.9M) exceed its long term liabilities ($24.2M).


Debt to Equity History and Analysis

Debt Level: CPIX's debt to equity ratio (35.5%) is considered satisfactory.

Reducing Debt: CPIX's debt to equity ratio has increased from 2.2% to 35.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CPIX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CPIX is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 1.2% per year.


Next Steps

Dividend

What is Cumberland Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CPIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CPIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPIX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CPIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

A. Kazimi (62 yo)

21.92yrs

Tenure

US$1,477,297

Compensation

Mr. A. J. Kazimi, MBA founded Cumberland Pharmaceuticals Inc. in 1999 and has been its Chairman and Chief Executive Officer since 1999. Mr. Kazimi serves as the President of Cumberland Pharmaceuticals, Inc...


CEO Compensation Analysis

Compensation vs Market: A.'s total compensation ($USD1.48M) is above average for companies of similar size in the US market ($USD561.50K).

Compensation vs Earnings: A.'s compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
A. Kazimi
Founder21.92yrsUS$1.48m38.51%
$ 17.3m
Michael Bonner
CFO and Senior Director of Finance & Accounting4.83yrsUS$273.07k0.13%
$ 60.5k
Leo Pavliv
Executive VP of Operations & Chief Development Officerno dataUS$675.84k1.1%
$ 494.6k
James Herman
Senior VP of National Accounts & Chief Compliance Officer4.17yrsUS$353.59k0.30%
$ 132.8k
Martin Cearnal
Executive VP16.92yrsUS$462.64k1.01%
$ 452.2k
Jean Marstiller
Senior VP of Administrative Services & Corporate Secretaryno dataUS$298.01kno data
Cindy Patton
Senior Director of Field Marketing0.33yrno datano data
John Hamm
Director of Corporate Development0.83yrno datano data
Adam Mostafa
MD & Consultant1.83yrsno datano data
Erin Gull
Senior Corporate Relations Associateno datano datano data

1.8yrs

Average Tenure

65yo

Average Age

Experienced Management: CPIX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
A. Kazimi
Founder21.92yrsUS$1.48m38.51%
$ 17.3m
Martin Cearnal
Executive VP16.92yrsUS$462.64k1.01%
$ 452.2k
Joseph Williams
Member of Pharmaceutical Advisory Boardno datano datano data
Joey Jacobs
Lead Independent Directorno dataUS$89.90k0.62%
$ 278.4k
James Jones
Independent Director10.92yrsUS$65.98k0.091%
$ 40.8k
Robert Roberts
Member of Medical Advisory Boardno datano datano data
Gordon Bernard
Chairman of Medical Advisory Board & Independent Directorno dataUS$95.00kno data
J. Hix
Member of Pharmaceutical Advisory Boardno dataUS$233.65kno data
David Warrell
Member of Medical Advisory Boardno datano datano data
Timothy Meakin
Member of Pharmaceutical Advisory Boardno datano datano data
Ben deBoisblanc
Member of Medical Advisory Boardno datano datano data
Jonathan Griggs
Independent Director & Member of Pharmaceutical Advisory Board21.92yrsUS$65.98k0.092%
$ 41.1k

19.4yrs

Average Tenure

71yo

Average Age

Experienced Board: CPIX's board of directors are seasoned and experienced ( 19.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cumberland Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cumberland Pharmaceuticals Inc.
  • Ticker: CPIX
  • Exchange: NasdaqGS
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$44.810m
  • Shares outstanding: 15.04m
  • Website: https://www.cumberlandpharma.com

Number of Employees


Location

  • Cumberland Pharmaceuticals Inc.
  • 2525 West End Avenue
  • Suite 950
  • Nashville
  • Tennessee
  • 37203
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CPIXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2009
CBJDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2009

Biography

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care and gastroenterology in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 23:10
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.